Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
Phase 1
Recruiting
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- Drug: TimoD implantDevice: Injector system
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- EyeD Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT06321562
- Locations
- 🇩🇪
Breyer, Kaymak & Klabe Augenchirurgie, Düsseldorf, Germany
🇩🇪Universitäts-Augenklinik Heidelberg, Heidelberg, Germany
🇩🇪Universitätsaugenklinik Magdeburg, Magdeburg, Germany
© Copyright 2025. All Rights Reserved by MedPath